https://scholars.lib.ntu.edu.tw/handle/123456789/520260
標題: | Validation of an Epstein-Barr virus antibody risk stratification signature for nasopharyngeal carcinoma by use of multiplex serology | 作者: | Simon J Liu Z Brenner N Yu K.J Hsu W.-L CHENG-PING WANG Chien Y.-C Coghill A.E Chen C.-J Butt J Proietti C Doolan D.L Hildesheim A Waterboer T. |
關鍵字: | Epstein-Barr virus; Multiplex serology; Nasopharyngeal carcinoma; Risk stratification signature; Validation | 公開日期: | 2020 | 出版社: | American Society for Microbiology | 卷: | 58 | 期: | 5 | 來源出版物: | Journal of Clinical Microbiology | 摘要: | Serological testing for nasopharyngeal carcinoma (NPC) has recently been reinvigorated by the implementation of novel Epstein-Barr virus (EBV)-specific IgA and IgG antibodies from a proteome array. Although proteome arrays are well suited for comprehensive antigen selection, they are not applicable for large-scale studies. We adapted a 13-marker EBV antigen signature for NPC risk identified by proteome arrays to multiplex serology to establish an assay for large-scale studies. Taiwanese NPC cases (n=175) and matched controls (n=175) were used for assay validation. Spearman's correlation was calculated, and the diagnostic value of all multiplex markers was assessed independently using the area under the receiver operating characteristic curve (AUC). Two refined signatures were identified using stepwise logistic regression and internally validated with 10-fold cross validation. Array and multiplex serology showed strong correlation for each individual EBV marker, as well as for a 13-marker combined model on continuous data. Two refined signatures with either four (LF2 and BGLF2 IgG, LF2 and BMRF1 IgA) or two (LF2 and BGLF2 IgG) antibodies on dichotomous data were identified as the most parsimonious set of serological markers able to distinguish NPC cases from controls with AUCs of 0.992 (95% confidence interval [CI], 0.983 to 1.000) and 0.984 (95% CI, 0.971 to 0.997), respectively. Neither differed significantly from the 13-marker model (AUC, 0.992; 95% CI, 0.982 to 1.000). All models were internally validated. Multiplex serology successfully validated the original EBV proteome microarray data. Two refined signatures of four and two antibodies were capable of detecting NPC with 99.2% and 98.4% accuracy. Copyright ? 2020 American Society for Microbiology. All Rights Reserved. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85084025047&doi=10.1128%2fJCM.00077-20&partnerID=40&md5=dbef9de38c6e3ff50faf8703da4ef07f https://scholars.lib.ntu.edu.tw/handle/123456789/520260 |
ISSN: | 0095-1137 | DOI: | 10.1128/JCM.00077-20 | SDG/關鍵字: | immunoglobulin A antibody; immunoglobulin G antibody; proteome; virus antibody; virus antigen; immunoglobulin A; virus antibody; virus antigen; area under the curve; Article; cancer risk; cancer staging; controlled study; diagnostic value; Epstein Barr virus; human; major clinical study; microarray analysis; multiplex serology; nasopharynx carcinoma; priority journal; receiver operating characteristic; sensitivity and specificity; serology; Taiwanese; validation study; carcinoma; Epstein Barr virus; Epstein Barr virus infection; genetics; nasopharynx carcinoma; nasopharynx tumor; risk assessment; Antibodies, Viral; Antigens, Viral; Carcinoma; Epstein-Barr Virus Infections; Herpesvirus 4, Human; Humans; Immunoglobulin A; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Risk Assessment |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。